We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Novel Multivariate Blood Test Improves Multiple Sclerosis Disease Management

By LabMedica International staff writers
Posted on 06 Sep 2023
Print article
Image: The Octave MSDA Test is a multi-protein serum-based biomarker assay to measure disease activity of MS patients (Photo courtesy of Shutterstock)
Image: The Octave MSDA Test is a multi-protein serum-based biomarker assay to measure disease activity of MS patients (Photo courtesy of Shutterstock)

Multiple sclerosis (MS) is a complex ailment with considerable diversity, impacting each patient uniquely, which complicates diagnosis and prognosis. Effectively managing disease activity, which involves new neurological symptoms and relapse rates, is central to improving outcomes. Historically, there have been no dynamic, quantifiable methods to track disease activity over time. This creates challenges in MS management and could lead to less-than-optimal utilization of disease-modifying therapies, which are essential for reducing disease activity, minimizing relapses, and slowing disease progression. Now, a new blood test has demonstrated potential for offering quantitative insights to enhance the care of MS patients and deliver a superior performance compared to the top-performing single-protein model.

Octave Bioscience (Menlo Park, CA, USA) has developed the Octave MSDA Test, which is the first and only multi-protein serum-based biomarker assay devised to quantitatively measure the disease activity of MS patients. This test can be used throughout a patient's disease journey, enabling more informed clinical decisions for improved disease management. The Octave MSDA Test is part of the comprehensive Octave Precision Care Solution, which combines data from the test along with expanded imaging capabilities and clinical insights, providing a more comprehensive view of the patient. This solution equips the entire MS care ecosystem with the means to better gauge, monitor, and manage the disease.

Octave has completed evaluating over 1,400 protein biomarkers using more than 3,000 patient samples. Advanced data science, machine learning, and feature extraction techniques were harnessed to select the top-performing and most pertinent 18 biomarkers for incorporation into a customized assay panel, developed using the Olink proteomics platform. These biomarkers were then integrated into an algorithm, generating four pathway scores that represent distinct disease processes in MS pathophysiology – immunomodulation, neuroinflammation, myelin biology, and neuroaxonal integrity. Additionally, the algorithm produces an overall disease activity score on a scale of 1.0 to 10.0.

The Octave MSDA Test boasts numerous clinical applications throughout the care continuum. It aids in routine surveillance to better monitor disease activity, especially in patients with stable disease, and to track emerging or worsening symptoms. Furthermore, it can be used as an objective assessment of treatment response and tracks a patient’s disease activity level once a decision has been made with their clinician to scale back or discontinue their disease-modifying treatment. The Octave MSDA Test promotes shared decision-making between patients and their physicians while complementing standard radiographic imaging and clinical evaluation to offer more objective insights for enhanced MS care. This test has been successfully clinically validated relative to radiographic and clinical markers of disease activity and has outperformed the top-performing single-protein model. Presently, the Octave MSDA Test is available for commercial use and is being routinely utilized in leading practices across the United States, as well as in pharmaceutical studies.

“We are encouraged that these results validate the performance of the Octave MSDA Test and demonstrate its ability to quantitatively and objectively measure disease activity of patients with MS,” said Ferhan Qureshi, Vice President of Biomarker Product Development at Octave. “The test interrogates multiple biological pathways important in MS pathophysiology with a diverse set of biomarkers to provide a highly sensitive, dynamic perspective of disease at the subclinical level. This provides an important complement to clinical evaluation of signs and symptoms of disease and MRI findings.”

Related Links:
Octave Bioscience 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.